Reducing the Risk of Thrombotic Events
0 FOLLOWERS
Thrombotic events don't always come with a warning. That's why this series, Reducing the Risk of Thrombotic Events, discusses options that can treat and help protect patients against thrombotic events such as cardiovascular death, myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism.
Reducing the Risk of Thrombotic Events
3y ago
Host: Jennifer Caudle, DO
Guest: Sandeep Nathan, MD
Tune in as Dr Sandeep Nathan discusses treatment guidelines for thrombotic risk reduction in patients with chronic CAD/PAD and shares data on these patients from the REACH Registry. Dr Nathan will also explain a different treatment paradigm, dual pathway inhibition, using XARELTO® 2.5 mg twice daily plus low-dose aspirin once daily for the reduction in the risk of major cardiovascular events.
This promotional educational activity is brought to you by Janssen Pharmaceuticals, Inc., and is not certified for continuing medical education. The con ..read more
Reducing the Risk of Thrombotic Events
3y ago
Host: Jennifer Caudle, DO
Guest: Steven Fein, MD
Here to delve into venous thromboembolism (VTE) clinical trial data on XARELTO®, a treatment option approved for deep vein thrombosis (DVT) and pulmonary embolism (PE), is Dr Steven Fein. He will highlight the EINSTEIN clinical trials, a subgroup analysis, and the results of a randomized, open-label pilot trial for the treatment of DVT and/or PE in patients with active cancer.
This promotional educational activity is brought to you by Janssen Pharmaceuticals, Inc., and is not certified for continuing medical education. The consultant is a paid s ..read more